文献速递放疗物理与技术泌尿生殖与妇科肿瘤放疗胸部肿瘤放疗

新型高性能环形机架CBCT成像系统在前列腺癌和肺癌患者中的剂量计算准确性

Dose calculation accuracy of a new high-performance ring-gantry CBCT imaging system for prostate and lung cancer patients.
PubMed 文献 · Radiother Oncol · 2024-10-24

本研究比较了HyperSight CBCT与计划CT的HU-质量密度校准曲线,并对20例前列腺癌和20例肺癌患者评估DVH参数差异及3D全局伽马通过率。结果显示前列腺癌剂量计算准确,肺癌因呼吸运动伪影影响剂量计算准确性。

要点

  • HyperSight CBCT与计划CT的HU值在每个校准模体插入物上一致在35 HU以内。
  • 前列腺癌PTV Dmean、V95%和V107%最大偏差分别为1.8%、-1.1%和<0.1%。
  • 肺癌PTV V95%中位偏低1.1%、V107%中位偏高1.1%,与呼吸运动伪影有关。

核心结论

  • HyperSight CBCT对前列腺癌患者可实现准确剂量计算,无需实施特定的HyperSight CBCT-质量密度曲线。
  • 对肺癌患者,呼吸运动妨碍了准确剂量计算。

研究设计与样本

  • 比较HyperSight CBCT与计划CT的HU-质量密度校准曲线,并对20例前列腺癌和20例肺癌患者评估DVH参数差异及3D全局伽马通过率。
  • 将第一分次采集的HyperSight CBCT与计划CT刚性配准,传播CT上的勾画,并在HyperSight CBCT上重新计算剂量。

主要发现

  • 每个HU-质量密度校准模体插入物上,HyperSight CBCT与计划CT的HU值一致在35 HU以内。
  • 前列腺癌PTV Dmean、V95%和V107%最大偏差分别为1.8%、-1.1%和<0.1%。
  • 肺癌PTV V95%中位偏低1.1%、V107%中位偏高1.1%,归因于呼吸运动伪影。
  • 2%/2mm伽马平均通过率(±SD)前列腺癌患者为98.7%±1.2%,肺癌患者为96.2%±2.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The recently introduced high-performance CBCT imaging system called HyperSight offers improved Hounsfield units (HU) accuracy, a larger CBCT field-of-view and improved image quality compared to conventional ring gantry CBCT, possibly enabling treatment planning on CBCT imaging directly. In this study, we evaluated whether the dose calculation accuracy on HyperSight CBCT was sufficient for treatment planning in prostate and lung cancer patients. MATERIALS AND METHODS: HyperSight CBCT was compared to planning CT (pCT) in terms of HU-to-mass density (MD) calibration curves. For twenty prostate patients and twenty lung patients, differences in DVH parameters, and 3D global gamma between dose distributions calculated on pCT and free breathing HyperSight CBCT were evaluated. For this purpose, HyperSight CBCT acquired at the first fraction was rigidly registered to the pCT, delineations from the CT were propagated and the dose was recalculated on the HyperSight CBCT. RESULTS: For each insert of the HU-to-MD calibration phantom, the HU values of HyperSight CBCT and pCT agreed within 35 HU. For prostate maximum deviations in PTV Dmean, V95% and V107% were 1.8 %, -1.1 % and < 0.1 % respectively. For lung PTV V95% was generally lower (median -1.1 %) and PTV V107% was generally higher (median 1.1 %) on HyperSight CBCT due to breathing motion artifacts. The average (±SD) 2 %/2mm gamma pass rate was 98.7 %±1.2 % for prostate cancer patients and 96.2 %±2.1 % for lung cancer patients. CONCLUSION: HyperSight CBCT enabled accurate dose calculation for prostate cancer patients, without implementation of a specific HyperSight CBCT-to-MD curve. For lung cancer patients, breathing motion hampered accurate dose calculations.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sijtsema ND, Penninkhof JJ, van de Schoot AJAJ, et al. Dose calculation accuracy of a new high-performance ring-gantry CBCT imaging system for prostate and lung cancer patients. Radiother Oncol. 2024. PMID: 39454887. doi:10.1016/j.radonc.2024.110596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。